Healthcare / Medical Care FacilitiesThailand
$13.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $188.5M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.8B
P/E
11.7x
↓EV/EBITDA
8.9x
↓ROE
13.6%
↑Gross Margin
24.4%
↓Debt/Equity
0.65
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.6%
FCF CAGR
-11.2%
FCF margin
15.2%
FCF / Net income
1.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.74B · net income $295.1M · FCF $416.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.74B | $2.74B | $2.74B | $2.35B | $3.37B |
| Net Income | $295.1M | $295.1M | $493.0M | $419.7M | $1.03B |
| EBITDA | $571.6M | $571.6M | $692.9M | $700.8M | $1.48B |
| EPS | — | — | 1.65 | 1.40 | 3.44 |
| Gross Margin | 24.4% | 24.4% | 30.7% | 31.1% | 45.1% |
| Operating Margin | 12.8% | 12.8% | 18.1% | 21.6% | 37.8% |
| Net Margin | 10.8% | 10.8% | 18.0% | 17.9% | 30.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.65 | 0.65 | 0.79 | 0.61 | 0.47 |
| Current Ratio | 0.73 | 0.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $416.7M | $416.7M | $-93.9M | $188.5M | $594.6M |
| Returns | |||||
| ROE | 13.6% | 13.6% | 24.2% | 20.5% | 45.9% |
| Valuation | |||||
| P/E | 11.71 | 11.71 | 12.91 | 19.82 | 8.71 |
| EV/EBITDA | 8.90 | 8.90 | 11.31 | 13.15 | 6.59 |
| P/B | 1.76 | 1.76 | 3.13 | 4.06 | 4.00 |
| Growth & Yield | |||||
| Revenue Growth | 0.1% | 0.1% | 16.6% | -30.2% | — |
| EPS Growth | — | — | 17.9% | -59.3% | — |
| Dividend Yield | 4.9% | 4.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.6%
Start / end P/E
n/dx → n/dx
EPS bridge
1.65 → n/d
Residual
-16.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.